Cutaneous Neuroimmune Crosstalk in Chronic Dermatoses

Abstract

Chronic dermatoses, such as atopic dermatitis, psoriasis, and chronic urticaria, represent a significant clinical challenge due to their multifactorial etiologies and recalcitrant nature. Recent advances have highlighted the pivotal role of neuroimmune crosstalk within the skin microenvironment, implicating a bidirectional interplay between neural and immune cells that perpetuates cutaneous inflammation and symptomatology. This review synthesizes the current understanding of neuroimmune interactions in chronic dermatoses, elucidates mechanistic pathways, evaluates risk factors, and discusses clinical implications, diagnostic considerations, and therapeutic targets based on the latest evidence and guideline recommendations.

Introduction

The skin is increasingly recognized not only as a physical barrier but also as a dynamic, immunologically active organ with extensive innervation. Chronic dermatoses are characterized by persistent inflammation, pruritus, and relapsing courses, underscoring the involvement of both the nervous and immune systems. The crosstalk between cutaneous nerves and immune cells orchestrates a complex network of mediators, including neuropeptides, cytokines, and growth factors, which modulate disease expression and severity. Understanding these interactions is crucial for developing targeted interventions and improving disease outcomes in clinical practice.

Epidemiology / Disease Burden

Chronic dermatoses affect millions globally, contributing to considerable morbidity, reduced quality of life, and socioeconomic burden. Atopic dermatitis has a global prevalence of up to 20% in children and 3% in adults, while psoriasis affects about 2-3% of the population. Chronic urticaria, though less prevalent, poses significant management challenges due to its unpredictable course. The chronicity and symptom burden of these diseases, particularly pruritus and psychosocial distress, underscore the necessity for a deeper understanding of their underlying pathobiology, including the neuroimmune axis.

Pathophysiology

Neuroimmune crosstalk in chronic dermatoses involves bidirectional signaling between peripheral sensory nerves and immune cells such as mast cells, dendritic cells, and T lymphocytes. Cutaneous nerves release neuropeptides (e.g., substance P, calcitonin gene-related peptide) that can activate immune cells, leading to the release of pro-inflammatory cytokines (e.g., IL-4, IL-31, TNF-α). Conversely, immune-derived mediators can sensitize or stimulate sensory nerves, perpetuating itch and inflammation. In atopic dermatitis, for example, increased nerve fiber density and elevated neurotrophins (e.g., nerve growth factor) drive pruritus and T helper 2 (Th2)-skewed inflammation. Psoriasis illustrates robust IL-17/IL-23 axis activation, with emerging data supporting neural modulation of cytokine networks. Chronic urticaria demonstrates mast cell-neuronal interactions that exacerbate wheal formation and itch.

Risk Factors

Genetic predisposition, environmental exposures (allergens, irritants), stress, and infections are recognized risk factors for chronic dermatoses. Notably, psychological stress enhances neuropeptide release and disrupts skin barrier function, amplifying neuroimmune signaling. Genetic variations in neuroimmune pathway genes (e.g., filaggrin, IL-31, TRPV1) further modulate individual susceptibility and disease chronicity. Understanding these risk determinants is essential for risk stratification and patient education.

Clinical Features

Chronic dermatoses share common clinical hallmarks: persistent erythematous plaques, scaling, excoriation, and intractable pruritus. Neuroimmune crosstalk manifests clinically as heightened itch perception, alloknesis, and lichenification due to repetitive scratching. In atopic dermatitis, flexural involvement and sleep disturbances predominate, with frequent psychosomatic comorbidity. Psoriasis typically presents with well-demarcated plaques and joint involvement, while chronic urticaria is characterized by recurrent wheals and angioedema, often with nocturnal exacerbation. Recognition of neuroimmune-driven symptoms is critical for comprehensive assessment and management.

Diagnosis

Diagnosis remains primarily clinical, supplemented by histopathology, laboratory tests (e.g., IgE, inflammatory markers), and, in select cases, neuropeptide quantification or nerve fiber density assessment. Emerging biomarkers reflecting neuroimmune activity, such as serum IL-31 and substance P, are under investigation for their diagnostic and prognostic utility. Differential diagnosis should consider systemic diseases, infections, and drug reactions that may mimic chronic dermatoses. Early identification of neuroimmune mechanisms may guide personalized therapy.

Treatment & Management

Management of chronic dermatoses targets both immune and neurogenic components. Topical corticosteroids, calcineurin inhibitors, and emollients remain foundational, aiming to suppress inflammation and restore barrier function. Systemic therapies (e.g., cyclosporine, methotrexate, biologics) are reserved for moderate-to-severe disease. Antihistamines, gabapentinoids, and selective neurokinin-1 receptor antagonists (e.g., aprepitant) address neurogenic itch. Behavioral interventions, stress management, and patient education complement pharmacotherapy. Multidisciplinary care, incorporating dermatologists, allergists, and mental health professionals, optimizes patient outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in elucidating neuroimmune pathways and developing targeted therapies. Biologics inhibiting IL-4/IL-13 (dupilumab) and IL-17/IL-23 (secukinumab, guselkumab) have transformed the management of atopic dermatitis and psoriasis, respectively, offering rapid and sustained disease control. Novel agents targeting neuroimmune mediators, such as IL-31 inhibitors (nemolizumab) and JAK inhibitors (baricitinib, upadacitinib), have demonstrated efficacy in refractory pruritus and inflammation. Topical TRPV1 antagonists and neuropeptide modulators are under clinical evaluation. These advances herald a paradigm shift towards personalized, mechanism-based therapeutic strategies.

Guideline Recommendations

International guidelines emphasize a stepwise, individualized approach, incorporating disease severity, comorbidities, and patient preferences. Early intervention, comprehensive symptom control, and minimization of adverse effects are prioritized. Recent guidelines advocate for the integration of novel biologics and targeted small molecules for moderate-to-severe disease unresponsive to conventional therapy. Emphasis is also placed on addressing psychosocial factors, patient education, and long-term monitoring for treatment safety and efficacy.

Conclusion

Cutaneous neuroimmune crosstalk represents a central mechanism driving the pathogenesis, symptomatology, and chronicity of dermatoses such as atopic dermatitis, psoriasis, and chronic urticaria. Advances in understanding these pathways have informed the development of targeted therapies, transforming patient management and outcomes. Continued research into neuroimmune interactions, biomarker discovery, and novel interventions promises further progress in the precision care of chronic dermatoses, underscoring the importance of multidisciplinary, evidence-based approaches for optimal patient care.